Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 infusion during elective PCI to reduce periprocedural myocardial injury
2013-001967-22Phase 2Terminated
- Sponsor
- Papworth Hospital NHS Foundation Trust
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of Glucagon-like peptide 1 in myocardial infarction (MI), periprocedural myocardial injury and coronary arteriosclerosis, sponsored by Papworth Hospital NHS Foundation Trust. Primary endpoint: Incidence of myocardial infarction associated with coronary angioplasty or stenting (MI4a). Started Jun 2014; status: terminated.
02
Drugs
Glucagon-like peptide 1
03
Conditions
myocardial infarction (MI)periprocedural myocardial injurycoronary arteriosclerosis
Beyond the preview
Go deeper on 2013-001967-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001967-22.